论文部分内容阅读
目的:分析促红细胞生成素减少贫血患者输血量的临床效果。方法:选取广东省中西医结合医院2015年5月至2016年5月120例贫血患者作为研究对象,以随机分配为原则,分为观察组和对照组各60例。观察组患者通过促红细胞生成素进行治疗,对照组患者通过输血进行治疗,分析促红细胞生成素的临床疗效。结果:两组患者经过治疗后,血红蛋白均有明显上升,和治疗前相比,差异具有统计学意义(P<0.05),组间比较,差异无统计学意义(P>0.05);观察组输血量明显减少,与对照组输血量比较,差异具有统计学意义(P<0.05),观察组不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。结论:促红细胞生成素治疗贫血患者具有良好的临床疗效,能纠正贫血,减少输血量和输血风险。在贫血治疗的过程中,需要结合患者的实际情况,根据病情选择合理的方式。
Objective: To analyze the clinical effect of erythropoietin in reducing blood transfusion in patients with anemia. Methods: A total of 120 anemia patients from May 2015 to May 2016 in Guangdong Provincial Hospital of Integrated Traditional Chinese and Western Medicine were selected as the research objects. Randomly allocated as the principle, 60 cases were divided into observation group and control group. Patients in the observation group were treated with erythropoietin, and patients in the control group were treated with blood transfusion to analyze the clinical efficacy of erythropoietin. Results: After treatment, the hemoglobin in both groups increased significantly, compared with that before treatment, the difference was statistically significant (P <0.05). There was no significant difference between the two groups (P> 0.05) (P <0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion: Erythropoietin has a good clinical curative effect in patients with anemia, which can correct anemia, reduce blood transfusion and blood transfusion risk. In the course of anemia treatment, patients need to be combined with the actual situation, according to the disease to choose a reasonable way.